For the quarter ended March 2025, Steris (STE) reported revenue of $1.48 billion, up 4.3% over the same period last year. EPS came in at $2.74, compared to $2.41 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $1.48 billion, representing a surprise of -0.09%. The company delivered an EPS surprise of +5.79%, with the consensus EPS estimate being $2.59.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Steris performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Healthcare: $1.06 billion versus $1.05 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.9% change.
- Revenues- Healthcare Products- Consumables: $352.74 million versus $355.87 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6% change.
- Revenues- Healthcare Products- Capital equipment: $318.03 million compared to the $329.58 million average estimate based on three analysts. The reported number represents a change of -4.1% year over year.
- Revenues- Healthcare Products- Service: $386.41 million versus the three-analyst average estimate of $367.62 million. The reported number represents a year-over-year change of +12.5%.
- Revenues- Life Sciences: $149.47 million compared to the $158.82 million average estimate based on three analysts. The reported number represents a change of -7% year over year.
- Revenues- Applied Sterilization Technologies (AST): $273.89 million versus $269.92 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.2% change.
- Revenues- Life Sciences- Service: $36.45 million versus $44.18 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -20.7% change.
- Revenues- Life Sciences- Capital equipment: $36.98 million compared to the $40.52 million average estimate based on two analysts. The reported number represents a change of -16.4% year over year.
- Revenues- Life Sciences- Consumables: $76.04 million versus the two-analyst average estimate of $77.15 million. The reported number represents a year-over-year change of +8%.
- Operating income / (loss)- Healthcare: $279.71 million versus the two-analyst average estimate of $255.95 million.
- Operating income / (loss)- Corporate and Other: -$99.31 million versus -$83.07 million estimated by two analysts on average.
- Operating income / (loss)- Applied Sterilization Technologies (AST): $122.20 million compared to the $118.69 million average estimate based on two analysts.
View all Key Company Metrics for Steris here>>>
Shares of Steris have returned +4.6% over the past month versus the Zacks S&P 500 composite's +9.9% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
STERIS plc (STE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
